Business Context and Reporting Period
Company: Hyperscale Data, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 1, 2025
Reporting Period: Events occurring between July 24, 2025, and July 31, 2025.
Business Overview: The Company is incorporated in Delaware and trades on the NYSE American under the symbols GPUS (Class A Common Stock) and GPUS PD (Series D Preferred Stock).
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial metric disclosed relates to debt conversion:
- Convertible Note Conversion: Approximately $117,771 of an outstanding convertible note was converted into equity on July 30, 2025.
Note: The filing text does not provide clear values for total debt, liquidity, or operating performance metrics.
Material Changes
The filing reports unregistered sales of equity securities (Item 3.02) resulting in significant changes to the capital structure during late July 2025:
- July 24, 2025: Issued 5 shares of Class A Common Stock upon conversion of Class B Common Stock.
- July 25–31, 2025: Issued 2,890,755 shares of Class A Common Stock upon conversion of approximately 1,689.50 shares of Series B Convertible Preferred Stock.
- July 30, 2025: Issued 200,265 shares of Class A Common Stock upon conversion of the convertible note mentioned above.
- Total Outstanding Shares: As of July 31, 2025, the Company had 25,353,782 shares of Class A Common Stock outstanding.
All issuances were made in reliance on the Section 4(a)(2) exemption from registration under the Securities Act of 1933.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, outlook, or management discussion regarding future operations or strategy.
Risks and Contingencies: No specific risks or contingencies are detailed in this report beyond the standard disclosure of unregistered securities sales.
Investor Verification Checklist
- Verify the impact of the 3,091,025 newly issued shares on existing shareholder dilution.
- Confirm the remaining balance of the convertible note and Series B Convertible Preferred Stock post-conversion.
- Review the Company's most recent 10-Q or 10-K for comprehensive financial health metrics (revenue, cash flow, total debt) not included in this 8-K.
- Check for any subsequent filings regarding the valuation of the converted securities.